Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single-dose of ART5803 Following IVIG Administration in Healthy Participants

NCT06753955 is registered in ClinicalTrials.gov with Arialys Therapeutics as lead sponsor.

NCT NCT06753955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06753955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single-dose of ART5803 Following IVIG Administration in Healthy Participants
Lead sponsor
Arialys Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 25, 2025
Completion date
August 19, 2025
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune encephalitis, autoimmune encephalitis caused by n-methyl d-aspartate receptor antibody, autoimmune encephalitis caused by n-methyl d-aspartate receptor antibody (disorder)